Eli Lilly (LLY) made headlines with positive results from the Phase 3 BRUIN CLL-314 clinical trial for Jaypirca, marking a significant advancement in treatment options for chronic lymphocytic leukemia ...

BlackRock Health Sciences Trust offers a resilient 8.63% dividend yield, low expense ratio, and conservative, low-risk ...

Novo Nordisk A/S stock dips after 2025 guidance cut. However, click for why NVO's strong GLP-1 prospects, growing pipeline, ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. Ozempic and Rybelsus helped Novo gain share over Eli Lilly's once-weekly ...

Novo Nordisk stocks plunged by 7% in premarket trading following an announcement by the company that it has lowered its ...

Candymaker Mars pledges $2 billion for domestic operations through 2026, building on $6 billion invested over the past five ...

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

A total of 5 analyst ratings have been received for Teva Pharmaceutical Indus, with the consensus rating being Buy. The ...

If you're looking to add a few ETFs to your portfolio, the following three from Vanguard are good options. One covers a large part of the U.S. market, one is dividend-focused, and one gives you ...

The majority of liver cancer cases could be prevented by reducing levels of viral hepatitis, alcohol consumption and MASLD (metabolic dysfunction-associated steatotic liver disease – previously called ...